Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From what I've been told those not won't conert. They were paid ic cash, as well Aprils will be
RGBP Merger Post Was NOT Approved By David Koos or the Company.
It was False, Fraudulent, Misrepresentation and an Intentional Ploy to Milead the Public-Shareholders.
RGBP has Issued Two 8K's concerning this matter. The latest was this morning 5/10/19.
If the Link below does not open or work, go to Marketwatch and enter RGBP Ticker to locate it.
https://www.marketwatch.com/investing/Stock/rgbp/SecFilings?subview=secarticle&sid=27408109&guid=13419040&type=8
RGBP Has Put Out Two 8K's to Address this Fraudulent Release.
They may pursue Legal Action as well.
https://www.marketwatch.com/investing/Stock/rgbp/SecFilings?subview=secarticle&sid=27408109&guid=13419040&type=8
Item 7.01. Regulation FD Disclosure.
This is Amendment No. 1 to our Form 8-K that we filed with the Securities and Exchange Commission on May 8, 2019 (the “ Prior Form 8-K ”). The purpose of this Amendment No. 1 is to further confirm and expand on the disclosures set forth in the Prior Form 8-K as follows:
• The press release referenced in the Prior Form 8-K and stating that the Company had initiated a reverse merger with Aregen Bioscience Inc. (the “ Press Release ”) is entirely a false and misleading press release that contains serious material factual misrepresentations.
• We have not had, as of this date, any discussions, negotiations, or any dealings with Aregan Bioscience, Inc. or any representatives of that company or any other persons regarding any business combination including, but not limited to, a reverse merger or acquisition.
• We do not know who or why anyone would publish and disseminate such false and misleading statements regarding the Company and its affairs.
• We have no relationship with any of the persons who prepared, published, and disseminated the Press Release.
• We did not participate in the preparation and the dissemination of the Press Release, we were not asked to participate in the preparation and dissemination of the Press Release and we had no basis to believe or anticipate that any such Press Release was being issued, disseminated, and otherwise published.
• We did not authorize that press release and we had no expectation that any such press release was to be published or disseminated by anyone.
• We are entirely appalled by the actions of those who prepared and published the Press Release and we caution our stockholders and others to remain vigilant in disregarding suspicious public statements and other published “press releases” claiming to disclose our affairs unless there is a clear basis to confirm that the statements and press releases have been issued by us.
As appropriate, we may take further action to ensure that our stockholders and the market fully understand that we remain vigilant in upholding and conducting our affairs consistent with best practices and the requirements of the law.
Probably done so by the Admins/Monitors of IHub-People can't just take down your message
(LLY) Provides Compunds for RGBP to work with. There is a definitive agreement-they aren't just screening for (LLY)
# of Shares owned doesn't matter-Pikers Cry loudest.
HemaXellerate Trials were done outside of the US-Discovering a larger market - Bone Marrow Suppression.
Ever hear of a Company called Barofold Corp? Around for years. They made it to Phase II Clinical Trials with the FDA for a New Drug-Failed.
$20 Million was dumped into Barofold over time. Intellectual Properties, Patents, FDA Trials-They came up short sold to another company they believe can take their process to the next level successfully for $150,000Cash-$150,000 shares.
Things don't always work out.
As far as Eli Lilly goes-yep they supply RGBP with Compunds-there is a definitive agreement in place. (LLY) allows RGBP to recieve compounds from (LLY) for drug discovery purposes, allow RGBP to Share information on compounds of mutual interest.
The agreement also grants (LLY) an option to negotiate w/RGBP including but not restricted to a compound purchase agreement, a license agreement, or a research collaboration agreement and development of material of mutual interest.
Is an agreement not a deal in different words?
I never said RGBP had a buyout, merge, agreement did I.
Stay Professional there Sid-You're Looking Fabulous.
What? Trips-Highly Doubtful
the only comparison is that Parent copany Subsidiaries that spin off, some do trade independently-Not Comaping Size OXY - Alan?
Of course they aren't as big as alphabet. The Point was you or another said subsidiaries don't trade independently, they do.
Pepsi's Profitable Spinoff.
In September 1997, Pepsico (NYSE:PEP) spun-off its Pizza Hut, KFC and Taco Bell restaurants into a separate company. Existing shareholders received one share in the new company, Tricon Global Restaurants (changed to YUM Brands (NYSE:YUM) in 2002), for every 10 shares of Pepsi.
Expert on RGBP-Never Claimed that, but have worked with them 5 years now.
ETNI 8K Out Today-
Alphabet's portfolio encompasses several industries, including technology, life sciences, investment capital, and research. Some of its subsidiaries include Google, Calico, Chronicle, GV, CapitalG, Verily, Waymo, X, and Google Fiber. Some of the subsidiaries of Alphabet have altered their names since leaving Google and becoming part of the new parent company—Google Ventures becoming GV, Google Life Sciences becoming Verily and Google X becoming just X. Following the restructuring, Page became CEO of Alphabet and Sundar Pichai took his position as CEO of Google.[4][5] Shares of Google's stock have been converted into Alphabet stock, which trade under Google's former ticker symbols of "GOOG" and "GOOGL".
All Google Shares were converted to Alphabet, Inc. Shares
Unless of course those companies spin off my the parent to trade independently.
Or in a Merge/Buyout Like Alphabet Inc. ? Se they bought Google, became Google's Parent, yet Google and some of it's subsidiaries still trade under the GOOG-GOOGL Tickers.
Some day they just may. And you find that funny?
What's worth .0001 per share?
And your point?
No Clue What ??? is, I'm not a mind reader.
Most companies have subsidiaries.
ETNI was ENTB-Change of name, probably means moving away from Stem Cell-NR2F6.
Zander is strictly a Veterinary NR2F6 Program (Cancers & Auto Immunes for Cats and Dogs, & EIPH Treatments and Therapies for Horses.
Zander is currently still a subsidiary of ETNI, they are spinning off, will have their own ticker, Zander recently paid a dividend in shares of Zander to all ETNI shareholders.
Tere are things going on behing the scenes so to speak. That's all I can say for now, they're both in a Quiet Period
BMSN is the Parent of RGBP, Why wouldn't they own shares?
CSAXQ just filed for Chapter 7 Bankruptcy
Astounding!! BMSN is the Parent of RGBP
RGBP is the Parent of ENTB-Now ETNI
ETNI is the Parent of Zander
The Latter 2 were licensed by RGBP to use NR2F6
Who wants who to think they got in early?
Zander is in a quiet period. ETNI/ENTB did receive their Dividends on June 12th as promised.
RGBP is near the completion of optimizing it's lead NR2F6 small molecule agonist. The process was near completion 3/21/18, with primary and backup compounds being readied for the final pre-clinical mouse experiments.
At that time (3/21) they were preparing to test the compounds in different mouse models of autoimmunity. The final dosing experiments were set to commence at that point, should be completed shortly, or may have been. Then they will move onto the efficacy studies in mice.
We could see news on these results soon.
The NR2F6 programs to identify antagonists of NR2F6 in an effort to unleash the cancer killing potential of a patients own immune system, as well as identifying agonists which should surpress the immune system in diseases where the immune system is over-activated, such as autoimmunity
I doubt you'll see any news on BMSN, they are RGBP's parent, but ther than that aren't involved
Quiet period right now can't say much at all. Perhaps they will fill the void with a company not in the space they currently are/were in. The name change is an indication of sorts.
Yes PBIO is lacking Buy Volume. Not liquid. Great company, not enough support. We-Small Cap Solutions, LLC have taken a break from working with them. May resume in a month or so.
BMSN is the Parent company of RGBP. Yes they hold majority, but that's it.
Insignificant, you bear no influence what so ever, sorry. The depressed share price in large has to do with financing, and how they get it.Very difficult for small companies like RGBP to obtain financing anywhere. What thwey have raised is with known people, but even they want at least some of their $'s back. So when restricted shares mature, come due, they sell. The price lasy year ran up near 400%, but Rule 144, comes due, and price retraces.
How many shares do you own?
The reason No large pharma has offered a merge, buyout as of yet is their program like NR2F6 is not quit as advanced yet like the companies that are small like them. Those companies were about 6 months to a year ahead of RGBP in developing their Drug(s)
That being said RGBP has made great strides and advancements since 2014.
Both Ichims remain in an Advisory capacity. They have added a Former Exec from Eli Lily, Tow from CVS Healthcare to the Board.
HemaXellerate IND# apllied Feb 2013-Approved March 2013
Patient Trials do exiist for HemaXellerate, but the focus moved to a much larger market other than aPlastic Anemia-Focus went to Bone Marrow Supression, Auto Immunes and NR2F6
dCellVax is encompassed also in NR2F6 Oncology/Cancer Patient Trials exist using Patients Own immune systems
BMSN is a different company than RGBP
In the last year two companies were purchased by Bristol Myer Squibb & Eli Lilly-they bought companies with similar programs to RGBP NR2F6 Program. They are/were both about six months to a year ahead of RGBP
Things are progressing Sciientifically just fine
The Shares struggle to move up, you are correct due to more shares maturing/coming due that belong to people that invested. Some do what some or all of their money back after time
I know an Alan from many other boards-Always Negative-Never Found a Stock he liked
He had multiple Names-You can tell by the wording and thought process-
So are SanDiegoAlan-Alan and maybe two others all the same? Hmmm
IP Check
Secretly? What I post has a Disclaimer-It divuges what's paid, and by who. All above board-No Secrets-Its for Dissemination, Exposure, Etc.
Every Company Public or Not has IR-Media-Ads-for the company and or product. Many can afford TV
If you are referring to what RGBP is paying as a retainer to Small Cap Solutions, LLC $1,000 a month. It is $12,000 per year. Pays the Mortgage. Nancy Pelosi LOL
They do have other clients, Four in all with different higher contract values which won't be divulged, and a phone room, all in all Six figures a year ain't bad it all for the entirety, for working Market Hours.
So you keep on "Posting for Free" The Jokes on You archer111
Most Every Single Company pays for IR, Advertising, Dissemination of Information and /or products. Do they not.
Name one Stock You Own that does not DogFish44
What? Value Quest is a 3rd Party that pays Small Cap Solutions, LLC for Marketing Consultation, IR, and Media Relations.
Why would you think I assume they are Regen?
Two Separate Entities.
Major Progression in the Oncology Immunology
BioTechs are Hot Again
#RGBP (Regen BioPharma, Inc.) & #LLY (Eli Lilly)
Working Together (Auto Immune Diseases/Disorders & Cancers - Therapies - Oral Drugs)
https://www.linkedin.com/pulse/major-progression-oncology-immunology-sector-rob-kreh/ …
Investors Signal Strong Support As $PBIO Converts Additional $7.24 Million In Debt To Equity-Exceeding $13.6 Million Past 30 Days
https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5172714-investors-signal-strong-support-pbio-converts-additional-7_24-million-debt-equity-exceeding …
$PBIO 2018 Expected to Result in $100's of Thousands in New Sales/Revenue-New Multi Billion $ Markets are the Catalyst
CBD OILS-CLEAN FOODS-NUTRACEUTICALS-PROTEIN BASED DRUGS-BIO PHARMA & More
Retired Half of Debt $6.39 M-3 New Instruments Due Out By YE - Have You Researched Pressure BioSciences, Inc
https://www.linkedin.com/pulse/tapping-new-multi-billion-markets-expected-result-100s-rob-kreh/ … …
$PBIO 2018 Expected to Result in $100's of Thousands in New Sales/Revenue-New Multi Billion $ Markets are the Catalyst
CBD OILS-CLEAN FOODS-NUTRACEUTICALS-PROTEIN BASED DRUGS-BIO PHARMA & More
Retired Half of Debt $6.39 M-3 New Instruments Due Out By YE - Have You Researched Pressure BioSciences, Inc
https://www.linkedin.com/pulse/tapping-new-multi-billion-markets-expected-result-100s-rob-kreh/ … …
$PBIO Have You Noticed-Researched
Converted $6.39 Mil (Half) Debt to Equity
9th Consecutive Qtr Increases Sales/Revenue
New Markets Opening to Create $100's of Thousands New Sales/Revenue
CBD OILS-Bio Pharma Manufacturing-Protein Based Drugs-Clean Foods
https://www.linkedin.com/pulse/tapping-new-multi-billion-markets-expected-result-100s-rob-kreh/ … …